Amgen (NSDQ:AMGN) announced today that it successfully completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX). Thousand Oaks, Calif.-based Amgen has officially acquired South San Francisco-based Five Prime for $38 per share in cash, reaching an equity value of approximately $1.9 billion. The acquisition was initially announced on March 4, 2021. As of the […]
Oncology
Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
Oncopeptides announced today that it submitted an application for European marketing authorization of its melflufen therapeutic. Conditional marketing authorization from the European Medicines Agency (EMA) is the aim for the company after its pivotal phase 2 Horizon study provided positive outcomes with melflufen (melphalan flufenamide) in treating relapsed refractory multiple myeloma, according to a news […]
OncoSec wins CE mark for electroporation device to treat solid tumors
OncoSec Medical (NSDQ:ONCS) announced today that it received CE mark approval for its next-generation device to enable better uptake of anti-cancer therapies. GenPulse, part of OncoSec’s electroporation device platform for treating solid tumors, is designed to apply short electric impulses to a tumor, according to a news release. Get the full story at our sister site, […]
Terumo launches therapeutic interventional oncology team
Terumo (TSE: 4543) announced that it has launched a global therapeutic interventional oncology team, effective April 1, 2021. Leuven, Belgium-based Terumo said in a news release that team’s introduction reflects its aspiration to be a global leader in the interventional oncology space by focusing on improving quality of life and survival. Team members work in […]
TriSalus, University of Texas to collaborate on solid tumor treatment study
TriSalus Life Sciences and the University of Texas today announced a collaboration to evaluate the treatment of solid tumors. The Texas MD Anderson Cancer Center and TriSalus will collaborate on treatments for tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint […]
Pyxis Oncology closes $152M Series B
Biologics developer Pyxis Oncology announced today that it closed a Series B financing round worth $152 million. Cambridge, Mass.-based Pyxis had its financing round co-led by Arix Bioscience and RTW Investments. Existing investors including Leaps by Bayer, Longwood Fund, Agent Capital and Ipsen also contributed to the $152 million, which brings Pyxis’ total funding to […]
Oncopeptides launches Pepaxto multiple meyeloma treatment
Oncopeptides (STO:ONCO) announced today that it launched its Pepaxto drug for treating relapsed or refractory multiple myeloma. Boston-based Oncopeptides’ Pepaxto (melphalan flufenamide), which received accelerated FDA approval on Feb. 26, is now commercially available and the first patients are being treated with the drug, according to a news release. Pepaxto received approval in combination with […]
How Bionaut Labs aims to tackle brain tumors with microrobots
The roboticist Michael Shpigelmacher was one of the founders of PrimeSense, a robotic 3-D vision technology company Apple acquired in 2013. PrimeSense created technology empowering the Microsoft Xbox Kinect and the iPhone’s Face ID feature, allowing users to use facial recognition to unlock their phones. Now Shpigelmacher has set his sights on drug-delivery with Bionaut […]
Bicara Therapeutics launches with $40M investment
Bicara Therapeutics announced today that it has launched with a $40 million investment from Biocon Limited. Cambridge, Mass.-based Bicara’s financing is earmarked for the advancement of its pipeline of first-in-class bifunctional antibodies developed between an engineering team in Bangalore, India, and the Cambridge-based executive team, according to a news release. Bicara’s pipeline includes tumor-targeted antibodies […]
AVEO to collaborate with Bristol Myers Squibb on renal cell carcinoma drugs
AVEO Oncology (NSDQ:AVEO) announced today that it entered into a clinical trial collaboration with Bristol Myers Squibb. Boston-based AVEO’s collaboration and supply agreement with Bristol Myers Squibb is slated to evaluate Fotivda (tivozanib) in combination with Opdivo (nivolumab), an anti-PD-1 therapy developed by Bristol Myers Squibb. The drugs will be evaluated in a pivotal Phase […]
